Loading...

Catherine Smith, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Phone415-476-9553
ORCID ORCID Icon0000-0003-0160-7026 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Duke University, Durham, NCM.D.05/2002School of Medicine
    Yale University, New Haven, CTB.S.05/1998Chemistry
    Collapse Awards and Honors
    American Association of Cancer Research20152015 Next Gen Star Award
    European Hematology Association/American Society of Hematology2010Translational Research Training Program Award
    Leukemia and Lymphoma Society 2010  - 2013Special Fellow in Clinical Research Career Development Award
    Duke University School of Medicine2002American Medical Women’s Association, Inc. Janet M. Glasgow Memorial Achievement Citation
    Duke University School of Medicine2002E. E. Owen, M.D. Clinical Scholar Award
    Duke University School of Medicine2001Alpha Omega Alpha
    Duke University School of Medicine2001William G. Anylan Scholarship
    Yale University1998Cum Laude
    Yale University1998Howard Douglass Moore Prize in Chemistry
    Yale University1998Michael T. Manzella Award

    Collapse Overview 
    Collapse Overview
    My laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML). We have a particular emphasis on AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is mutated in ~30% of AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. We employ a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows us to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows us to devise ways to circumvent these evolutionary adaptations.

    We have the following specific research focuses at the current time:
    1) Rational discovery and screening of novel FLT3 inhibitors coupled with analysis of resistance mechanisms to clinically relevant FLT3 inhibitors currently in clinical trials.
    2) Identification and validation of non-FLT3 dependent mechanisms of FLT3 inhibitor resistance through genomic analysis of patients treated on FLT3 inhibitor clinical trials.
    3) Study of the role of AML genetic tumor heterogeneity in response and resistance to FLT3 inhibitor therapy.
    4) Understanding the molecular mechanism of recurrent cyclin D3 mutations in mediating resistance to FLT3 inhibitor therapy.

    Collapse Research 
    Collapse Research Activities and Funding
    Investigating Resistance to FLT3 Inhibitors in AML
    NIH/NCI K08CA187577Sep 1, 2014 - Aug 31, 2018
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse Websites
    Collapse In The News
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Benjamin Demaree, Cyrille Delley, Cheryl Peretz, Harish Vasudevan, David Ruff, Aik Ooi, Catherine C. Smith, Adam Abate. Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones. Blood. 2019 Nov 13; 134(Supplement_1):2088-2088.
      View in: Publisher Site
    2. Cheryl A Cohler Peretz, Lisa H F McGary, Tanya F Kumar, J Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, Chunxiao Zhang, Mark J. Levis, Alexander E. Perl, Anskar Yu Hung Leung, Catherine C. Smith. Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib. Blood. 2019 Nov 13; 134(Supplement_1):1440-1440.
      View in: Publisher Site
    3. Kelly L. Schoenbeck, Giselle Salmasi, Miguel Carlos Cerejo, Patricia A. Cornett, Lloyd E. Damon, Aaron C. Logan, Rebecca L. Olin, Andrew D. Leavitt, Catherine C. Smith. Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms. Blood. 2019 Nov 13; 134(Supplement_1):1165-1165.
      View in: Publisher Site
    4. Kelly L. Schoenbeck, Miguel Carlos Cerejo, Patricia A. Cornett, Lloyd E. Damon, Karin L. Gaensler, Andrew D. Leavitt, Aaron C. Logan, Gabriel N. Mannis, Rebecca L. Olin, Giselle Salmasi, Peter H. Sayre, Neil P. Shah, Anand Dhruva, Chloe E. Atreya, Catherine C. Smith. Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution. Blood. 2019 Nov 13; 134(Supplement_1):5859-5859.
      View in: Publisher Site
    5. Varun Mittal, Mimi Lo, Lloyd E. Damon, Karin L. Gaensler, Thomas G. Martin, Rebecca L. Olin, Catherine C. Smith, Aaron C. Logan. Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Blood. 2019 Nov 13; 134(Supplement_1):5089-5089.
      View in: Publisher Site
    6. Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia. 2019 Sep 12. PMID: 31511612.
      View in: PubMed
    7. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2020 Jan; 26(1):189-196. PMID: 31493541.
      View in: PubMed
    8. McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019 Aug; 9(8):1050-1063. PMID: 31088841.
      View in: PubMed
    9. Smith CC. Roman warfare: targeting of support cells in AML. Blood. 2019 02 07; 133(6):506-507. PMID: 30733203.
      View in: PubMed
    10. Dennis J. Eastburn, Christine M. McMahon, Robert Durruthy-Durruthy, Martin Carroll, Catherine C. Smith, Alexander E. Perl. Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response. Blood. 2018 Nov 29; 132(Supplement 1):1476-1476.
      View in: Publisher Site
    11. Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Maria R. Baer, David F. Claxton, Joseph G. Jurcic, Ellen K. Ritchie, Stephen A. Strickland, Raoul Tibes, Jason E. Hill, Matt Rosales, Erkut Bahceci. Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations. Blood. 2018 Nov 29; 132(Supplement 1):1458-1458.
      View in: Publisher Site
    12. Li-Wen Huang, Chiung-Yu Huang, Charalambos Andreadis, Aaron C. Logan, Gabriel N. Mannis, Catherine C. Smith, Karin M. Gaensler, Thomas G. Martin, Lloyd E. Damon, Michael A. Steinman, Rebecca L. Olin. Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies. Blood. 2018 Nov 29; 132(Supplement 1):3599-3599.
      View in: Publisher Site
    13. Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 07; 19(7):889-903. PMID: 29859851.
      View in: PubMed
    14. Mark J. Levis, Catherine Choy Smith, Koji Ishizuka, Ken Kobayashi, Meena Arunachalam, Yibin Wang, Deborah Lazzaretto, Jorge E. Cortes. Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3 -ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):7017-7017.
      View in: Publisher Site
    15. Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 08; 18(8):1061-1075. PMID: 28645776.
      View in: PubMed
    16. Jessica K. Altman, Alexander E. Perl, Jorge E. Cortes, Catherine Choy Smith, Mark Robert Litzow, Jason E Hill, Richard A. Larson, Charles Liu, Ellen K. Ritchie, Stephen Anthony Strickland, Eunice S. Wang, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, Mark J. Levis. Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):7003-7003.
      View in: Publisher Site
    17. Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017 07 06; 130(1):48-58. PMID: 28490572.
      View in: PubMed
    18. Catherine Choy Smith, Mark J. Levis, Mark Robert Litzow, Alexander E. Perl, Jessica K. Altman, Stan Gill, Geoffrey Yuen, Peter Bonate, Takeshi Kadokura, Angela Joubert James, Charles Liu, Itsuro Nagase, Ogert Fisniku, Erkut Bahceci. Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology. 2016 May 20; 34(15_suppl):7026-7026.
      View in: Publisher Site
    19. Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar; 1(3):e85630. PMID: 27158668.
      View in: PubMed
    20. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 07; 57(7):1560-6. PMID: 26490487.
      View in: PubMed
    21. Timothy Ferng, Catherine Choy Smith. Resistance to FLT3 Inhibitors. Resistance to Tyrosine Kinase Inhibitors. 2016 Jan 1; 131-145.
      View in: Publisher Site
    22. Catherine C. Smith, Mark J. Levis, Mark R Litzow, Alexander E. Perl, Jessica K. Altman, Stanley C. Gill, Takeshi Kadokura, Geoffrey J. Yuen, Ogert Fisniku, Charles Liu, Itsuro Nagase, Briana Sargent, Noreen Welter, Erkut Bahceci. Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study. Blood. 2015 Dec 3; 126(23):4836-4836.
      View in: Publisher Site
    23. Catherine C. Smith, Aaron D. Viny, Evan S. Massi, Cyriac Kandoth, Nicholas D. Socci, Henry Hsu, Brian West, Gideon Bollag, Barry S. Taylor, Ross L. Levine, Neil P. Shah. Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors. Blood. 2015 Dec 3; 126(23):677-677.
      View in: Publisher Site
    24. Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Ellen K. Ritchie, Richard A. Larson, Catherine Choy Smith, Eunice S. Wang, Stephen Anthony Strickland, Maria R. Baer, Mark Robert Litzow, David Claxton, Gary J. Schiller, Celalettin Ustun, Charles Liu, Stan Gill, Briana Sargent, Erkut Bahceci. Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). Journal of Clinical Oncology. 2015 May 20; 33(15_suppl):7003-7003.
      View in: Publisher Site
    25. Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun; 5(6):668-79. PMID: 25847190.
      View in: PubMed
    26. Frett B, McConnell N, Smith CC, Wang Y, Shah NP, Li HY. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur J Med Chem. 2015 Apr 13; 94:123-31. PMID: 25765758.
      View in: PubMed
    27. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. PMID: 25776193.
      View in: PubMed
    28. Gabriel N. Mannis, Thomas G. Martin, Lloyd E. Damon, Aaron C. Logan, Weiyun Ai, Karin M.L. Gaensler, Lawrence D. Kaplan, Anuj Mahindra, Rebecca L. Olin, Peter Sayre, Catherine C. Smith, Jeffrey L. Wolf, Jimmy Hwang, Charalambos Andreadis. Long-Term Outcomes of 133 Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with High-Dose Chemotherapy and Autologous Stem Cell Rescue in First Complete Remission. Biology of Blood and Marrow Transplantation. 2015 Feb 1; 21(2):s141-s142.
      View in: Publisher Site
    29. Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife. 2014 Dec 22; 3. PMID: 25531068.
      View in: PubMed
    30. Katherine A Minson, Catherine C Smith, Alisa B. Lee-Sherick, Deborah DeRyckere, Elisabeth Lasater, Amanda A. Hill, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Neil P. Shah, Douglas K. Graham. MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia. Blood. 2014 Dec 6; 124(21):3757-3757.
      View in: Publisher Site
    31. Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014 Nov 20; 9(4):1333-48. PMID: 25456130.
      View in: PubMed
    32. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44. PMID: 24894413.
      View in: PubMed
    33. Sudhindra A, Smith CC. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep. 2014 Jun; 9(2):174-85. PMID: 24682858.
      View in: PubMed
    34. Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 08; 111(14):5319-24. PMID: 24623852.
      View in: PubMed
    35. Rebecca L. Olin, Charalambos Andreadis, Thomas G. Martin, Jeffrey L. Wolf, Lawrence D. Kaplan, Weiyun Ai, Jeffrey M. Venstrom, Aaron C. Logan, Catherine C. Smith, Karin ML. Gaensler, Jimmy Hwang, Lloyd E. Damon. Comprehensive Geriatric Assessment Identifies Significant Functional Impairments in Older Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation. 2014 Feb 1; 20(2):s65-s66.
      View in: Publisher Site
    36. Gabriel N. Mannis, Lloyd E. Damon, Weiyun Ai, Charalambos Andreadis, Karin ML. Gaensler, Lawrence D. Kaplan, Aaron C. Logan, Anuj Mahindra, Rebecca L. Olin, Peter Sayre, Catherine C. Smith, Jeffrey M. Venstrom, Jeffrey L. Wolf, Thomas G. Martin. A Phase 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative Therapy for Autologous Stem Cell Transplant in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation. 2014 Feb 1; 20(2):s114-s115.
      View in: Publisher Site
    37. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22. PMID: 24374145.
      View in: PubMed
    38. Smith CC. Disease diversity and FLT3 mutations. Proc Natl Acad Sci U S A. 2013 Dec 24; 110(52):20860-1. PMID: 24324154.
      View in: PubMed
    39. Catherine C Smith, Kimberly Lin, Elisabeth Lasater, Whitney Stewart, Lauren E Damon, Andrew Kasarskis, Ali Bashir, Matthew Pendleton, Robert Sebra, Alexander E Perl, Mai H Le, Chao Zhang, Brian West, Neil P. Shah. Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML). Blood. 2013 Nov 15; 122(21):3938-3938.
      View in: Publisher Site
    40. Gabriel N. Mannis, Lloyd E Damon, Weiyun Z. Ai, Charalambos Andreadis, Karin ML Gaensler, Neel K. Gupta, Lawrence D. Kaplan, Andrew D. Leavitt, Aaron C. Logan, Rebecca L. Olin, Peter H. Sayre, Catherine C Smith, Jeffrey M Venstrom, Thomas G Martin. Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia. Blood. 2013 Nov 15; 122(21):2172-2172.
      View in: Publisher Site
    41. Collins BH, Holzknecht ZE, Lynn KA, Sempowski GD, Smith CC, Liu S, Parker W, Rockey DC. Association of age-dependent liver injury and fibrosis with immune cell populations. Liver Int. 2013 Sep; 33(8):1175-86. PMID: 23710620.
      View in: PubMed
    42. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18; 121(16):3165-71. PMID: 23430109.
      View in: PubMed
    43. Jesse W. Keller, Lloyd E. Damon, Lawrence D. Kaplan, Thomas G. Martin, Jeffrey L. Wolf, Weiyun Z. Ai, Charalambos Andreadis, Jeffrey M. Venstrom, Catherine C. Smith, Karin M.L. Gaensler, Jimmy Hwang, Rebecca L. Olin. Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Is Predictive of Serious Adverse Events and Overall Survival in Older Allogeneic Transplant Recipients. Biology of Blood and Marrow Transplantation. 2013 Feb 1; 19(2):s293-s294.
      View in: Publisher Site
    44. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013; 313-8. PMID: 23714533.
      View in: PubMed
    45. Alexander E Perl, Grace R Jeschke, Catherine C Smith, James K. Mangan, Selina M. Luger, Martin Carroll. Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance. Blood. 2012 Nov 16; 120(21):2453-2453.
      View in: Publisher Site
    46. Willard Cheng, Elisabeth Lasater, Catherine C Smith, Mouanoutoua Mokang, Yun Bao, Neil Shah. Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples. Blood. 2012 Nov 16; 120(21):2559-2559.
      View in: Publisher Site
    47. Catherine C Smith, Jason Chin, Elisabeth Lasater, Amy L. Paguirigan, Kimberly Lin, Whitney Stewart, Sara Salerno, Lauren E Damon, Mark J. Levis, Alexander E Perl, Kevin Travers, Andrew Kasarskis, Jerald P. Radich, Neil Shah. Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220. Blood. 2012 Nov 16; 120(21):674-674.
      View in: Publisher Site
    48. Catherine C Smith, Michael Brown, Wendy T Parker, Kimberly Lin, Kevin Travers, Susana Wang, Susan Branford, Neil Shah. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy. Blood. 2012 Nov 16; 120(21):917-917.
      View in: Publisher Site
    49. Catherine C Smith, Elisabeth Lasater, Melissa Mccreery, Kimberly Lin, Whitney Stewart, Lauren E Damon, Alexander E Perl, Grace R Jeschke, Mayumi Sugita, Martin Carroll, Scott C. Kogan, Neil Shah. Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants. Blood. 2012 Nov 16; 120(21):141-141.
      View in: Publisher Site
    50. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 Apr 15; 485(7397):260-3. PMID: 22504184.
      View in: PubMed
    51. Smith CC, Shah NP. Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2012; 685-9. PMID: 24451819.
      View in: PubMed
    52. Catherine C. Smith, Michael Brown, Jason Chin, Corynn Kasap, Sara Salerno, Lauren E. Damon, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, Neil Shah. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,. Blood. 2011 Nov 18; 118(21):3752-3752.
      View in: Publisher Site
    53. Catherine C. Smith, Alexander E Perl, Elisabeth Lasater, Chao Zhang, Grace R Jeschke, Lauren E. Damon, Martin Carroll, Neil P. Shah. PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro. Blood. 2011 Nov 18; 118(21):764-764.
      View in: Publisher Site
    54. Alexander E Perl, Grace R Jeschke, Catherine C. Smith, James K. Mangan, Selina M. Luger, Martin Carroll. Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance,. Blood. 2011 Nov 18; 118(21):3502-3502.
      View in: Publisher Site
    55. Catherine C. Smith, Jason Chin, Qi Wang, Sara Salerno, Lauren E. Damon, Jeremy P. Hunt, Mark J. Levis, Alexander E Perl, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, John Kuriyan, Neil Shah. Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia. Blood. 2011 Nov 18; 118(21):937-937.
      View in: Publisher Site
    56. Jorge E. Cortes, Alexander E Perl, Catherine C. Smith, Tibor Kovacsovics, Herve Dombret, Hartmut Dohner, Bjorn Steffen, Arnaud Pigneux, Philippe Rousselot, Juergen Krauter, Giovanni Martinelli, Elihu H. Estey, Alan K Burnett, Anthony D. Ho, Norbert Ifrah, Theo de Witt, Robert Corringham, Joyce James, David Lilienfeld, Eugen Leo, Guy Gammon, Mark J. Levis. A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results. Blood. 2011 Nov 18; 118(21):2576-2576.
      View in: Publisher Site
    57. Catherine C. Smith, Lauren E. Damon, Xiaotian Zhu, Sara Salerno, Neil Shah. Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants. Blood. 2011 Nov 18; 118(21):930-930.
      View in: Publisher Site
    58. Warren Fiskus, Catherine C. Smith, Jacqueline Smith, Scott C. Wise, Elisabeth Lasater, Lauren E. Damon, Sara Salerno, Allan Fleming, Ruben Reyes, Siddhartha Ganguly, Mark S. Berger, Tom J. Rutkoski, Joseph McGuirk, Neil Shah, Kapil N. Bhalla. Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations. Blood. 2011 Nov 18; 118(21):2611-2611.
      View in: Publisher Site
    59. Smith CC, Shah NP. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res. 2011 Nov 01; 17(21):6605-7. PMID: 21948230.
      View in: PubMed
    60. Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011; 2011:121-7. PMID: 22160023.
      View in: PubMed
    61. Kaimal AJ, Smith CC, Laros RK, Caughey AB, Cheng YW. Cost-effectiveness of private umbilical cord blood banking. Obstet Gynecol. 2009 Oct; 114(4):848-55. PMID: 19888044.
      View in: PubMed